Accessibility Menu
Axsome Therapeutics logo

Axsome Therapeutics

(NASDAQ) AXSM

Current Price$240.89
Market Cap$12.44B
Since IPO (2015)+2,665%
5 Year+229%
1 Year+136%
1 Month+3%

Axsome Therapeutics Financials at a Glance

Market Cap

$12.44B

Revenue (TTM)

$708.24M

Net Income (TTM)

-$188.30M

EPS (TTM)

-$3.74

P/E Ratio

-64.63

Dividend

$0.00

Beta (Volatility)

0.94 (Low)

Price

$240.89

Volume

1,357,612

Open

$244.08

Previous Close

$241.12

Daily Range

$236.47 - $248.15

52-Week Range

$96.09 - $260.19

Estimated Earnings Date

Aug 3, 2026

AXSM: Motley Fool Moneyball Superscore

72

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Axsome Therapeutics

Industry

Pharmaceuticals

Employees

1,220

CEO

Herriott Tabuteau, MD

Headquarters

New York City, NY 10007, US

AXSM Financials

Key Financial Metrics (TTM)

Gross Margin

92.60%

Operating Margin

-24.80%

Net Income Margin

-26.59%

Return on Equity

-260.01%

Return on Capital

-51.35%

Return on Assets

-26.39%

Earnings Yield

-1.55%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$12.44B

Shares Outstanding

51.46M

Volume

1.36M

Avg. Volume

868.09K

Financials (TTM)

Gross Profit

$655.82M

Operating Income

-$175.61M

EBITDA

-$172.72M

Operating Cash Flow

-$70.73M

Capital Expenditure

-$263.00K

Free Cash Flow

-$70.99M

Cash & ST Invst.

$305.11M

Total Debt

$219.90M

Axsome Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$191.20M

+57.4%

Gross Profit

$176.48M

+58.0%

Gross Margin

92.30%

N/A

Market Cap

$12.44B

N/A

Market Cap/Employee

$17.47M

N/A

Employees

712

N/A

Net Income

-$64.54M

-8.6%

EBITDA

-$61.08M

-11.4%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$305.11M

+1.4%

Total Debt

$219.90M

+4.1%

Accounts Receivable

$251.06M

+55.6%

Inventory

$31.52M

+93.1%

Long Term Debt

$146.08M

-30.1%

Short Term Debt

$73.82M

+3152.0%

Return on Assets

-26.39%

N/A

Return on Invested Capital

-64.00%

N/A

Free Cash Flow

-$20.82M

+52.4%

Operating Cash Flow

-$20.70M

+52.3%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ARWRArrowhead Pharmaceuticals, Inc.
$80.50+2.04%
CYTKCytokinetics, Incorporated
$87.26+6.17%
JAZZJazz Pharmaceuticals plc
$237.72+3.35%
NUVLNuvalent, Inc.
$123.51-0.01%

Trending Stocks

Symbol / CompanyPricePrice Chg
CMCSAComcast
$24.22+0.05%
AALAmerican Airlines Group
$17.92+0.00%
INTCIntel
$131.72+0.03%
NOKNokia
$13.03+0.00%

Questions About AXSM

What is the current price of Axsome Therapeutics?

Axsome Therapeutics is trading at $241.12 per share.

What is the 52-week range for Axsome Therapeutics?

Over the past 52 weeks, Axsome Therapeutics has traded between $96.09 and $260.19.

How much debt does Axsome Therapeutics have?

As of the most recent reporting period, Axsome Therapeutics reported total debt of $219.90M.

How much cash does Axsome Therapeutics have on hand?

Axsome Therapeutics reported $305.11M in cash and cash equivalents in its most recent financial results.

What is Axsome Therapeutics’s dividend yield?

Axsome Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.